Source: International Congress 2019 – Respiratory function assessment in disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Barros (Lisboa, Portugal), C. Mourato (Lisboa, Portugal), K. Budzak (Lisboa, Portugal), P. Araújo (Lisboa, Portugal), A. Oliveira (Lisboa, Portugal), J. Valença (Lisboa, Portugal), C. Bárbara (Lisboa, Portugal). Bronchodilator reversibility - differences between asthma and COPD. 1119

Member's Comments

No comment yet.

Related content which might interest you: Bronchodilator treatment for asthma and COPD Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Patterns of bronchodilator reversibility of FEV1 in asthma and COPD patients Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI Source: Virtual Congress 2020 – New imaging techniques applied to old problems Year: 2020 Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Bronchodilator reversibility in asthma and COPD: findings from three large population studies Source: Eur Respir J, 54 (3) 1900561; 10.1183/13993003.00561-2019 Year: 2019 The effect of tiotropium in COPD complicated with asthma Source: Annual Congress 2007 - New insights into the treatment of COPD Year: 2007 Bronchodilator reversibility is associated with non-adherence to inhalers in stable asthma patients, without airflow limitation. Source: Virtual Congress 2020 – Lung function diagnostics Year: 2020 Effects of ciclesonide on the management of stable COPD with airway eosinophilia Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Ventilation heterogeneity reversibility: asthma, COPD or ACOS? Source: International Congress 2017 – Novel imaging findings characterising various lung diseases and their prognoses Year: 2017 COPD and asthma overlap with bronchiectasis Source: Eur Respir Monogr 2018; 81: 167-185 Year: 2018 Smoking effect on airways inflammation in asthma and COPD: relationship with airways reversibility and hyperresponsiveness Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Assessment of lung volumes and capacities in bronchodilator reversibility changes of hyperinflation of COPD Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016 Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Severe exacerbations, decline in lung function and inhaled budesonide in asthma Source: Eur Respir J 2007; 30: Suppl. 51, 619s Year: 2007 The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype Source: International Congress 2015 – COPD and lung function: risk factors and outcomes Year: 2015 Difference between asthma and COPD patients in adherence and non-adherence patterns to inhaler devices Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Frequency of COPD exacerbations and severity of COPD Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Airway resistances deteriorate following spirometry in asthma and COPD patients Source: International Congress 2016 – Functional assessment of the airways Year: 2016